View More Recent Stories

Apr 29, 2025 03:33PM BeiGene (ONC) Says U.S. Patent and Trademark Office Invalidated Pharmacyclics Patent

Apr 7, 2025 06:20AM RBC Capital Starts BeiGene Ltd. (ONC) at Outperform

Apr 4, 2025 04:32AM Citizens JMP Reiterates Market Outperform Rating on BeiGene Ltd. (ONC)

Apr 3, 2025 06:09AM BeiGene (ONC) Provides Update on the Ociperlimab Clinical Development Program

Mar 31, 2025 06:29AM BeiGene (ONC) Receives Positive CHMP Opinion for TEVIMBRA

Mar 13, 2025 10:42AM BeiGene Ltd. (ONC) PT Raised to $259 at Bernstein After 'Asset and Market Model Updates'

Mar 4, 2025 06:19AM Bank Of Commerce (ONC) Announces TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

Mar 3, 2025 04:19PM JPMorgan Reiterates Overweight Rating on BeiGene Ltd. (ONC), PT $311

Mar 3, 2025 04:25AM BofA Securities Upgrades BeiGene Ltd. (ONC) to Buy

Feb 28, 2025 07:58AM BeiGene Ltd. (ONC) PT Raised to $348 at Guggenheim

Feb 28, 2025 04:20AM BeiGene Ltd. (ONC) PT Raised to $348 at Citizens JMP

Feb 27, 2025 06:04PM BeiGene Ltd. (ONC) PT Raised to $334 at TD Cowen

Feb 27, 2025 03:36PM BeiGene Ltd. (ONC) PT Raised to $308 at Jefferies

Feb 27, 2025 06:03AM BeiGene, Ltd. (ONC) Tops Q4 EPS by 77c, provides guidance

Jan 15, 2025 07:04AM Regulatory Approval Clears Path for Oncolytics Biotech (ONCY) to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Oct 4, 2024 07:00AM Oncolytics Biotech (ONCY) Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Sep 19, 2024 07:05AM Oncolytics Biotech (ONCY) Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

View More Recent Stories